Professional
Added to YB: 2024-06-07
Pitch date: 2024-05-31
MRNA [bullish]
Moderna, Inc.
-65.1%
current return
Author Info
No bio for this author
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Market Cap
$22.1B
Pitch Price
$139.75
Price Target
227.00 (+365%)
Dividend
N/A
EV/EBITDA
-5.56
P/E
-7.72
EV/Sales
7.86
Sector
Biotechnology
Category
growth
Moderna, Inc.: RSV Vaccine Approval Marks Beginning of Expansion Beyond Covid
MRNA: RSV vaccine approval marks expansion beyond COVID. Competing w/ GSK & PFE but convenience may help secure contracts. Pipeline in other areas (oncology, rare diseases) shows mRNA promise. No moat yet but making progress. Upside: cash infusion accelerates programs. Risks: competition, long-term COVID demand. PT $227 on recurring COVID revs + new launches: RSV in '24, combo in '25, cancer & rare disease. High uncertainty.
Read full article (11 min)